Infection with human cytomegalovirus (HCMV) modulates the expression of a number of cellular receptors and is known to inhibit expression of the epidermal growth factor receptor (EGFR), a cell surface receptor that can promote cell proliferation through a cascade of intracellular signalling events. We have examined the mechanisms by which HCMV mediates downregulation of EGFR expression and show that virus infection results in the profound upregulation of Wilms' Tumour 1 (WT1) protein, a transcription factor associated with the negative regulation of a number of growth factors and growth factor receptors, including EGFR. Moreover, chromatin immunoprecipitation experiments also show that HCMV infection results in increased binding of WT1 to the EGFR promoter. Finally, we show that depleting the cell of WT1 using small interfering RNA abrogates virus-mediated downregulation of EGFR. Taken together, our observations suggest that HCMV-mediated repression of EGFR expression results from a virusmediated increase in cellular WT1, a known pleiotropic regulator of mitogenesis, apoptosis and differentiation.
INTRODUCTION
Human cytomegalovirus (HCMV) is a ubiquitous betaherpesvirus that is rarely pathogenic in immunocompetent individuals and establishes lifelong persistence with latency following primary infection. However, in situations in which the immune system is compromised or immature (e.g. in organ transplantation and AIDS patients or following congenital infection), HCMV can cause serious pathology in multiple organ systems (Sweet, 1999) .
Work from a number of laboratories has shown that HCMV infection perturbs several important cellular processes, including the cell cycle, cellular transcription and immunoregulation; all of these are believed to optimize the infected cell for high levels of virus production and aid viral dissemination. HCMV can also interfere with the expression of a number of cellular receptors that are involved in receptor-mediated cell signalling. For instance, expression of both the tumour necrosis factor 1 receptor (TNFR1) (Baillie et al., 2003) and the epidermal growth factor receptor (EGFR) (Fairley et al., 2002) is repressed by HCMV infection. However, whilst HCMV disrupts TNFR1 expression by preventing transport of the receptor to the cell surface, it disrupts EGFR expression by reducing total steady state levels of EGFR RNA, probably by inhibition of transcription (Beutler et al., 2003; Fairley et al., 2002) . This has a physiological impact on the functionality of the EGFR since HCMV-infected cells show no epidermal growth factor (EGF)-mediated autophosphorylation of EGFR early in infection (Fairley et al., 2002) .
The EGFR is a 170 kDa transmembrane glycoprotein involved in a number of cellular signalling pathways such as MAPK, JAKs/STATs and phospholipid metabolic pathways (Jorissen et al., 2003) . EGFR is part of a complex signalling system important in normal cell physiology and is widely expressed in all tissues, where it can regulate diverse functions including mitogenesis, differentiation, apoptosis and migration (Wells, 1999 2007). Our own observations would suggest that any activation of EGFR-mediated signalling that does occur by virus binding is rapidly inhibited by an, as yet, unknown viral early gene product (Fairley et al., 2002) . We suggest that the virus uses cellular signals induced by EGFR activation for internalization and/or viral immediate early (IE) gene expression but then ensures that the cell becomes isolated from any further cell-mediated signalling which might compromise subsequent virus-specific signalling.
The EGFR promoter is a GC-rich region containing multiple transcriptional start sites and two separate enhancer domains but lacking classical CAAT and TATA boxes (Ishii et al., 1987; Maekawa et al., 1989) . EGFR promoter regulation is complex and its activity is modulated by a number of transcriptional activators such as p53 (Ludes-Meyers et al., 1996) and egr-1 (Nishi et al., 2002) , as well as repressors such as GCF2 (Rikiyama et al., 2003) , promyelocytic leukaemia (PML) (Vallian et al., 1998) , Wilms' Tumour 1 (WT1) (Englert et al., 1995) and TAp63 (Nishi et al., 2001) proteins. The mechanism by which HCMV inhibits expression of EGFR is, to date, unclear. Using cycloheximide/actinomycin D and phosphonoformate block experiments, which permit only viral IE expression and inhibit late gene expression, respectively, we have shown that early (E) gene products are required for the downregulation of expression of EGFR mRNA (Fairley et al., 2002) . In this report, we extend our analysis of HCMV-mediated EGFR downregulation by investigating the mechanism by which HCMV perturbs EGFR expression.
Our findings suggest that the reduction in steady state levels of EGFR mRNA during HCMV infection results from virus-induced expression of a known negative regulator of EGFR expression, WT1, which binds the EGFR promoter, resulting in its transcriptional repression.
METHODS
Cell culture, viruses and treatments. Passage 18-25 primary human foreskin fibroblasts (HFFs) were obtained from ATCC and used for all experiments. Cells were grown in Eagle's minimal essential medium (EMEM) (Gibco) supplemented with 10 % (v/v) fetal calf serum (EMEM-10) with penicillin (100 U ml 21 ) and streptomycin (100 U ml 21 ) at 37 uC in a humidified 5 % CO 2 atmosphere. Cells were infected with HCMV (Towne) as previously described (Murphy et al., 2002) . The endothelial tropical clinical isolate TB40/E was used where stated and has also been previously described (Sinclair et al., 2000; Sinzger et al., 2000) . After 18 h incubation cells were infected or mock-infected and total RNA was prepared as described below for dual EGFR/GAPDH PCR analysis.
For treatment of cells with EGF, cells were treated with 10 ng EGF ml 21 for 1 h prior to analysis.
RNA extraction and semiquantitative RT-PCR. Total RNA was extracted from HFFs with RNA-Bee reagent (Tel-Test.) according to the manufacturer's protocol. Total RNA (5 mg) was used for reverse transcription and made up to 14.5 ml with sterile water. Oligo dT (6 ml; Promega) was added to the sample and incubated at 70 uC for 5 min and quickly chilled on ice. Each sample was incubated with 15 ml RNase Inhibitor, 16 reverse transcription buffer (Biostat), 4 mM dNTPs, 50 U MMLV reverse transcriptase, at 42 uC for 60 min followed by incubation at 95 uC for 10 min and then quickly chilled on ice. TE buffer (50 ml, 0.16) was added to each sample. PCR was performed in 50 ml reaction mixture using the dual PCR kit, which contained primers for both EGFR and GAPDH (Biostat) (1 cycle 96 uC for 180 s, 32 cycles 94 uC for 60 s, 58 uC for 90 s and 72 uC for 90 s and a final step of 72 uC for 10 min).
PCR for repressors of EGFR [0.16 ml Taq buffer (Promega), 100 ng template cDNA, 200 mM each dNTP (Promega), 0.5 mM each primer (Promega) and 2 U Taq] was as follows: 1 cycle 95 uC for 5 min, 30 cycles 94 uC for 45 s, annealing temp. (described below) for 45 s, 72 uC for 90 s. Sequences of the PCR primers were as follows (the annealing temperature and size of the PCR product are given in parentheses): WT1, FP 59-GCGGAGCCCAATACAGAATA-39, RP 59-TCTCACCA-GTGTGCTTCCTG-39 (64 uC, 207 bp); GCF2, FP 59-GACTGTTT-GAGCCTGGAAGC-39, RP 59-CGATGGAGATGGAGGTGTCT-39 (64 uC, 250 bp); TAp63, FP 59-CATGAAGGTATAAGGAGTGTGT-39, RP 59-ACACACACTTAAAATATAGAGA-39 (68 uC, 280 bp); GAPDH, FP 59-GAGTCAACGGATTTGGTCGT-39, RP 59-TTGAT-TTTGGAGGGATCTCG-39 (64 uC, 263 bp). The reaction products were visualized by electrophoresis of 5 ml reaction mixture at 70 V for 40 min in 2 % agarose gel containing 0.5 mg ethidium bromide ml 21 .
Western blot analysis. Approximately 10 mg total cellular extracts were analysed by SDS-PAGE on 10 % polyacrylamide gels and transferred to Hybond C nitrocellulose (Amersham). Proteins were detected using 1 : 500 rabbit anti-WT1 (C-19) (Santa Cruz Biotechnology), 1 : 500 goat anti-EGFR (Santa Cruz Biotechnology) or 1 : 200 mouse anti-EGR1 (ABCAM 55160). Horseradish peroxidase-conjugated secondary antibodies (DAKO) were typically diluted 1 : 2000 and enhanced chemiluminescence reagents (Amersham) were used as described in the manufacturer's instructions.
Chromatin immunoprecipitation (ChIP) assay. Twenty-four hours after infection with HCMV, 2610 6 HFF cells were treated with 1 % formaldehyde and lysed, and aliquots were stored as input controls. ChIP assays were performed using anti-WT1 (C-19X) (Santa Cruz Biotechnology) and immunoprecipitated DNA was analysed by PCR with primers to the WT1 binding site in the EGFR promoter (FP 59-ACTTGACAGGGGAAACATGC-39, RP 59-CAAGGTCTGGGAA-CCACTGT-39). PCR conditions were 95 uC for 5 min and then 40 cycles at 94 uC (40 s), 50 uC (40 s) and 72 uC (90 s). WT1 knockdown analysis. Pre-validated WT1-specific small interfering RNA (siRNA) was purchased from Dhamacon as part of their siGENOME system. Stocks were made up to 20 mM and stored at 270 uC. WT1-specific or control siRNA (9.6 ml) was used to transfect HFF cells in a six-well plate using Lipofectamine-2000 according to the manufacturer's instructions (Invitrogen). At various times post-transfection, cells were analysed for WT1 expression by Western blot analysis (see above).
For those experiments using virus, WT1 knockdown was allowed to proceed for 48 h before infection with HCMV. To ensure that WT1 knockdown had no affect on the ability to support HCMV IE gene expression, cells were routinely assessed by immunofluorescence or IE Western blot analysis (E13 antibody, 1 : 500; Argene).
RESULTS

HCMV infection in primary fibroblasts reduces steady state levels of EGFR mRNA
Previous work in our laboratory has shown that HCMV infection of primary fibroblasts results in a profound decrease in total EGFR cellular protein (Fairley et al., 2002) and others have confirmed that this decrease in expression of EGFR is also reflected in the level of total EGFR RNA by Northern blot analysis (Beutler et al., 2003) . We wanted to confirm this decrease in EGFR expression by semiquantitative RT-PCR of EGFR mRNA.
A time-course analysis of HCMV-infected HFFs showed that EGFR mRNA was downregulated as early as 24 h postinfection (p.i.) and this downregulation was sustained to 48 h p.i., in comparison with uninfected controls (Fig. 1) . This correlates well with the time-course of downregulation of EGFR protein expression by HCMV (Fairley et al., 2002) . Interestingly, we routinely observed a modest, but reproducible, increase in EGFR levels within the first 6 h of infection, which might be consistent with an induction of EGFR resulting from virus binding to the EGF receptor, as has been suggested previously (Wang et al., 2003; and reviewed by Compton, 2004) Levels of WT1, a repressor of the EGFR, increase during HCMV infection
Although, formally, we cannot rule out that HCMV infection results in changes in steady state levels of EGFR mRNA due to mRNA turnover, it is also feasible that decreased EGFR expression is due to transcriptional effects. On this basis, we decided to analyse whether HCMV infection resulted in changes in any known transcriptional repressors of EGFR expression. There are a number of already identified cellular transcriptional factors that have been shown to repress transcription of EGFR. These include GCF2 (Rikiyama et al., 2003) , PML (Vallian et al., 1998) , WT1 (Englert et al., 1995) and TAp63 (Nishi et al., 2001) . Therefore, we wished to determine whether the levels of these known EGFR repressors changed during HCMV infection. RT-PCR analysis on HCMV-infected cells at 24 h p.i. indicated that while GCF2 levels stayed the same, and the levels of TAp63 only very modestly increased (approximately threefold) after HCMV infection, the expression of WT1 RNA increased dramatically as a response to infection ( Fig. 2a ). Furthermore, Western blot analysis of total protein levels clearly demonstrated that the observed increase in WT1 mRNA levels reflected an almost 10-fold increase in WT1 protein levels in HCMV-infected cells (Fig. 2b) . In contrast, levels of total PML, a protein which has been suggested to negatively regulate EGFR expression (Vallian et al., 1998) , did not appear to change significantly during HCMV infection (Fig. 2c) , consistent with previous observations (Ahn et al., 1998) .
WT1 binds to the EGFR promoter upon HCMV infection
Because there is an increase in mRNA and protein levels of the EGFR repressor WT1 following HCMV infection, we next wanted to determine whether HCMV infection led to increased binding of WT1 to the EGFR promoter.
Using ChIP assays, we analysed binding of WT1 to an already characterized binding site for this transcription factor on the EGFR promoter (Englert et al., 1995) . Fig. 3 shows that little or no WT1 can be detected binding to the EGFR promoter in control uninfected cells (lane 4), consistent with these cells expressing good levels of EGFR. In contrast, analysis of HCMV-infected cells at times when inhibition of EGFR expression was routinely observed resulted in detectable binding of WT1 to the EGFR promoter (lane 6), which was not observed using control antibody (lane 5).
WT1 knockdown abrogates the downregulation of EGFR by HCMV
On the basis that HCMV-induced upregulation of WT1 causes transcriptional repression of the EGFR promoter, we tested this directly by using siRNA to inhibit WT1 expression in HFF cells. Fig. 4(a) shows that WT1-specific siRNAs efficiently reduced WT1 expression. Fig. 4(b) also shows that this knockdown of WT1 had functional consequences in that it resulted in an increase in expression of the EGF-responsive gene EGR-1 when cells were treated with EGF. This is entirely consistent with the view that a reduction in WT1 results in an increase in EGFR which then allows cells to be more responsive to EGF (compare Fig. 4b lanes 2 and 4) .
As expected, HCMV induces downregulation of EGFR in the presence of a control irrelevant siRNA (Fig. 4c, lane 2) . However, this downregulation is abolished if infection is performed in WT1-depleted cells (Fig. 4c, lane 4) . This clearly supports the model of virus-induced WT1 inhibiting EGFR expression. Importantly, knockdown of WT1 has no effect on the ability of cells to support HCMV major IE gene expression, as both siRNA control and WT1 downregulated cell populations show equivalent levels of IE proteins (Fig. 4d ).
DISCUSSION
During infection, HCMV can modulate a number of important cellular functions such as cellular transcription, cell cycle control and immune regulation. This is often achieved through direct interaction between viral proteins and key cellular regulatory proteins (Fortunato et al., 2000) . Similarly, HCMV can also alter cell signalling pathways by targeting cellular receptors (Fairley et al., 2002; Baillie et al., 2003) . However, the mechanisms by which this occurs are unclear.
EGFR plays a key role in the activation of multiple signalling pathways involved in mitogenesis, apoptosis, protein secretion and differentiation (Wells, 1999) . Consequently, by modulating cellular EGFR expression, HCMV appears to isolate the infected cell thereby preventing it from responding to extracellular signals which might conflict with virus-specific signalling used to optimize the cell for efficient virus productive infection.
Our observations, using semiquantitative RT-PCR for EGFR mRNA, showing that EGFR mRNA is substantially reduced from 18 h p.i., are entirely consistent with previous qualitative analysis of EGFR levels of total RNA (Beutler et al., 2003) and of total cellular EGFR protein (Fairley et al., 2002) during HCMV infection.
Interestingly, our analysis also routinely detected a modest increase in EGFR mRNA at 6 h p.i. It has been suggested that EGFR is one of the entry receptors for HCMV (Wang et al., 2003) and that binding of HCMV to the cell surface delivers an EGF-like signal which is important for virus internalization or initiation of viral IE gene expression (Wang et al., 2003) , although this is controversial (Isaacson et al., 2007) . As activation of EGFR by ligation with EGF is known to result in transcriptional activation of EGFR expression (reviewed by Wells, 1999) , it is possible that the transient increase in EGFR mRNA observed shortly after HCMV infection is a result of EGFR stimulation by virion binding. Consequently, it is feasible that an initial induction of an EGF-like signalling cascade (at the very earliest time of infection) is important for virus entry or initiation of viral IE gene expression but, once this has occurred, the virus 'isolates' the infected cell from any further unwanted hostmediated signalling by efficiently downregulating the receptor. Consistent with this is the recent observation that HCMV binds to and needs to activate the PDGFb receptor for efficient infection (Soroceanu et al., 2008) but that this receptor is also subsequently downregulated in certain cell types by viral IE/E gene expression (Gredmark et al., 2007) .
There are a number of defined transcriptional regulators of the EGFR promoter which regulate EGFR expression both positively and negatively. Known transcriptional repressors of EGFR expression include the p53 homologue TAp63 (Nishi et al., 2002) , WT1 (Englert et al., 1995) , GCF2 (Rikiyama et al., 2003) and PML (Vallian et al., 1998) . Our analyses of the expression of these factors during HCMV infection showed that, in contrast to GCF2 and PML, expression of TAp63 was only moderately activated but expression of WT1 was substantially activated by virus infection.
WT1 is known to mediate transcriptional regulation of EGFR expression by binding directly to cognate WT1 binding sites in the EGFR promoter (Englert et al., 1995) . Crucially, HCMV infection not only increased WT1 expression at both the RNA and protein level, but also resulted in increased binding of WT1 to the EGFR promoter (confirmed by ChIP assays). This is entirely consistent with the inhibition of EGFR expression by HCMV being mediated by virus induction of WT1. This is supported by our observation that if WT1 is inhibited in infected cells, then EGFR downregulation is abolished.
We do not yet know which HCMV functions mediate this repression of EGFR. Other DNA viruses are also known to downregulate EGFR expression. For instance, an IE gene of herpes simplex virus, ICP0, has been shown to repress EGFR promoter activity and cell surface expression of EGFR protein (Liang et al., 2005) . Similarly, although adenovirus can mediate downregulation of EGFR expression by internalization and degradation of cell surface EGFR (Hoffman & Carlin, 1994) , an adenoviral IE equivalent, E1A, is also believed to inhibit EGFR transcription (Yan et al., 1991) . In contrast, HCMV IE gene expression is not sufficient for downregulation of EGFR protein (Fairley et al., 2002) . Additionally, HCMV DNA replication and true late gene expression are not required (Fairley et al., 2002) . Consequently, it is likely that an HCMV E gene(s) is responsible for this effect, although none of the US2-11 genes, which have a role in downregulation of MHC class 1, are involved (Fairley et al., 2002) .
In conclusion, our results suggest that the ability of HCMV to downregulate expression of cellular EGFR results, at least in part, from virus-mediated induction of a known negative regulator of EGFR expression, WT1, which results in the binding of WT1 to the EGFR promoter with concomitant repression of EGFR expression. As WT1 is known to be a pleiotropic effector of cellular gene expression involved in control of mitogenesis, apoptosis, protein secretion and differentiation, it is likely that the profound effect of HCMV on WT1 will not be limited to regulation of cellular EGFR. We predict that WT1 perturbation by HCMV will be reflected in multiple downstream cellular, and perhaps viral (Kim et al., 2000) , WT1 targets. Fig. 4 . Depletion of WT1 abrogates HCMV-mediated downregulation of EGFR. (a) HFF cells were transfected with control siRNA for 2 days (sicon) or with WT1-specific siRNA (siWT1) for 1 or 2 days. Samples were then analysed by Western blot with an anti-WT1-specific antibody. (b) Cells treated with control scrambled siRNA (con) or siRNAs specific to WT1 (WT1) for 2 days were then treated with EGF for 1 h and analysed for expression of the EGFR-responsive gene, EGR-1, by Western blot analysis. (c) EGFR levels were analysed by Western blot analysis in cells transfected for 48 h with either control (con) or WT1specific (WT1) siRNAs in uninfected cells (" HCMV) or cells infected with HCMV (+ HCMV) for 24 h. Data are representative of an individual experiment (n53). (d) HFF cells were transfected with control siRNA (sicon) or a WT1-specific siRNA (siWT1) and superinfected with HCMV (carrying an IE72-GFP fusion) overnight and then analysed for IE expression by Western blot analysis.
